J&J's Centocor To Develop Super Charged Antibodies Using Xencor's Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
Under the licensing deal, Centocor has rights to use Xencor's XmAb and Xtend technologies to develop and commercialize and antibodies.